Latest News
BrightFocus Foundation’s 2024 annual report highlights groundbreaking research and public awareness efforts over the last year to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
Motivated by his family’s experience with eye diseases, Dr. Miguel Flores-Bellver is searching for new biomarkers of age-related macular degeneration.
A BrightFocus-funded study examines how glaucoma affects a specific retinal cell involved in mood and sleep. This research could enhance treatment development and care for the individual as vision loss advances in glaucoma.
A clinical trial for an investigational eye drop to treat wet age-related macular degeneration is seeking eligible participants for enrollment.
The Alzheimer’s risk gene APOE4 puts women at greater risk for Alzheimer’s disease than men. New research suggests this may be caused by an interaction between blood and brain immune cells that appears before any cognitive symptoms.
Driven by a desire to make a meaningful impact on public health, National Glaucoma Research grant recipient Dr. Bingrui Wang is developing glaucoma prediction technology and tools for early detection.
BrightFocus Foundation Macular Degeneration Research grant recipient Maximilian Pfau, MD, aims to bridge this gap in available testing for AMD and detect the condition as early as possible. Learn more about his Macular Degeneration Research-funded project.
In This Issue:
- FDA Approves First-of-its-Kind Glaucoma Treatment
- President’s Corner
- AI Identifies New Genetic Targets for Glaucoma Treatment
- Six Common Glaucoma Eye Tests
- And more!
Alzheimer’s Disease Research, a BrightFocus Foundation program, was on the ground at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia to share insights on the latest research and foster scientific collaboration. Catch up on a few of the top headlines from AAIC.
In glaucoma, problems with mitochondria—a source of cell energy—can damage neurons that carry visual information from the eyes to the brain. Adriana Di Polo, PhD, is testing small molecule drugs that may prevent this damage and boost energy production in these neurons.
